Back to Journals » Open Access Journal of Clinical Trials » Volume 3
![](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The future of the pharmaceutical, biological and medical device industry
Authors Burgess LJ , Terblanche M
Published 7 September 2011 Volume 2011:3 Pages 45—50
DOI https://doi.org/10.2147/OAJCT.S22199
Review by Single anonymous peer review
Peer reviewer comments 4
Lesley J Burgess, Marli Terblanche
TREAD Research/Cardiology Unit, Department of Internal Medicine, Tygerberg Hospital and University of Stellenbosch, Parow, South Africa
Abstract: Numerous factors contribute to the declining pharmaceutical industry on the one hand and the rapidly growing generic industry together with the growing importance of medical devices and biologicals on the other. It is clear that the pharmaceutical industry is going to undergo a change in the next decade in order to meet the current challenges facing it and ultimately sustain its profitability and growth. This paper aims to identify a number of fairly obvious trends that are likely to have a significant impact on the product development pipeline in the next decade. It is more than clear that the current production pipeline for pharmaceutical, biotechnology and medical device industries is no longer sustainable and that urgent interventions are required in order to maintain its current level of profitability.
Keywords: pharmaceutical industry, personalized medicine, trends, generics, biotechnology
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.